1:57 PM Abstract No. 40 - Randomized phase II study of hepatic arterial embolization of hepatocellular carcinoma (HCC) with micospheres alone (bead block (BB)) versus doxorubicin loaded microspheres (LC bead (LCB))

Abstract

Purpose: To evaluate whether outcomes of trans-arterial chemoembolization (TACE) are inferior in patients 465 years old with hepatocellular carcinoma (HCC). Materials and Methods: A retrospective review of all patients who underwent TACE for the treatment of HCC between 2000 and 2010 was performed. Two groups (o1⁄4 65 years and 465 years of age) were compared based on ChildPugh score (CP), tumor/node/metastasis (TNM) stage, hepatitis B (HBV) or C (HCV) positivity, tumor number and size, number of TACE sessions and regimen used. Imaging outcomes were assessed based on modified Response Evaluation Criteria in Solid Tumors (mRECIST) to calculate tumor response and time to progression (TTP). Tumor response was defined as Complete or Partial Response. Disease control was defined as Stable Disease, and Complete or Partial Response. A p value o1⁄40.002 was deemed statistically significant. Results: A total of 179 treatments were performed in 97 patients, 42 of whom were 4 65. The groups had similar Child-Pugh status (p1⁄40.91), TNM stage (p1⁄40.37), HBV (p1⁄40.57), HCV (p1⁄40.1), tumor number (p1⁄40.27), tumor size (p1⁄40.61), number of treatments (p1⁄40.03) and drug type (p1⁄40.44). Tumor response was observed in 63.6% (35/55) in patients o1⁄465 and 57.1% (24/42) in those 465 (p1⁄40.52). Disease control was achieved in 69.0% (38/55) of patients o1⁄465 and 73.8% (31/42) in those 465 (p1⁄40.61). The mean time to progression was 245 days for patients o1⁄465 and 130.5 days for those 465 (p1⁄40.11). Conclusion: During a similar follow-up period, the efficacy of TACE for the treatment of HCC in elderly patients is comparable with that in a younger population. TACE should be considered a reasonable locoregional therapeutic option in elderly patients with HCC.